Tuesday, March 18, 2008

Interleukin Genetics Retains Top Life Science Communications Firms

Stern Investor Relations and LaVoie Group Selected as IR, praseodymium Agencies of
Record WALTHAM, Mass., March 18 /PRNewswire-FirstCall/ -- Interleukin
Genetics, Inc., (Amex: ), announced today that it have retained two
premier life scientific discipline communication theory firms, Stern Investor Relations, Inc.,
and LaVoie Group, as federal agencies of record to supply investor dealings and
public dealings services, respectively. The two houses will supply strategical advocate and execution, will lead
efforts to pass on Interleukin Genetics' vision to utilize the scientific discipline of
applied genetic science to personalise wellness direction and will back up the
Company's scheme to set up further partnerships and relationships
with biotechnology and pharmaceutical companies. Jerry Lee Lewis H. Bender, Head Executive Military Officer commented, "Interleukin
Genetics have a strong message on the value of diagnostic testing to empower
consumers to personalise their health. With the improver of these two
firms, I am confident that we will present our message more effectively to
our cardinal constituencies." About LaVoie Group LaVoie Group supplies strategic, incorporate selling and
communications- including selling strategy, corporate communications, as
well as public and investor dealings to life scientific disciplines and healthcare
companies. LaVoie Group's clients scope from start-ups to industry leaders. For more than information, visit . About Stern Investor Relations Stern Investor Relations supplies investor dealings consulting
services to biotechnology and healthcare companies. Stern iridium develops and
implements strategical investor dealings programmes designed to effectively
manage communication theory with the investing community. Founded in 1998, Stern
IR offers a full scope of investor dealings services. For more
information, delight visit . About Interleukin Genetics Interleukin Genetics, Inc. (Amex: ) is a genetics-focused
personalized wellness company that develops preventative consumer merchandises and
genetic diagnostic tests for sale to the emerging individualized wellness market. Focused
on the hereafter of wellness and medicine, Interleukin utilizes its prima genetics
research and scientific capablenesses to develop and diagnostic test innovative
preventive and curative products. Interleukin Genetics have developed and
commercialized familial diagnostic tests for hazard appraisal of coronary artery
disease, periodontic disease, and general nutrition. The Company currently
offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R),
Ginsana(R) and Venastat(R) which are sold at the nation's biggest food,
drug and mass retailers. Interleukin is headquartered in Waltham, MA. For
more information about Interleukin and its in progress programs, delight visit
. Certain statements contained herein are "forward-looking" statements
including statements regarding our ability to develop diagnostic,
personalized nutritionary and curative merchandises to forestall or treat
diseases of redness and other familial variations, our ability to
screen nutritionary chemical compounds for their personal effects on inflammatory responses
and other familial variations, given specific familial forms and our
ability to do advancement in advancing our core technologies. Because such
statements include hazards and uncertainties, existent consequences may differ
materially from those expressed or silent by such as as forward-looking
statements. Factors that could do existent consequences to differ materially
from those expressed or silent by such as forward- looking statements
include, but are not limited to, the hazard of marketplace credence of our
products, the hazard of engineering and merchandise obsolescence, holds in
product development, the public presentation of our commercial partners, the
availability of adequate capital, the actions of our rivals and other
competitive risks, and those hazards and uncertainnesses described in our
annual study on Form 10-K for the twelvemonth ended December 31, 2006 as amended,
filed with the Securities and Exchange Commission, our quarterly studies on
Form 10- Q and other filings made by us with the Securities and Exchange
Commission. We disclaim any duty or purpose to update these
forward-looking statements.

No comments: